Risankizumab与ustekinumab治疗斑块状银屑病的比较:一项批判性评价
本文批判性评价Gordon等开展的两项III期双盲随机对照试验(UltIMMa-1和UltIMMa-2),比较risankizumab与ustekinumab及安慰剂治疗中重度慢性斑块状银屑病的疗效与安全性。第16周时,risankizumab组达到PASI 90和sPGA 0或1的患者比例均显著高于ustekinumab组和安慰剂组(P < 0.001),不良事件频率在各治疗组间相似。
要点
- 第16周PASI 90:risankizumab组75.3%,ustekinumab组42.0%,安慰剂组4.9%(P < 0.001)。
- 第16周sPGA 0或1:risankizumab组87.6%,ustekinumab组63.0%,安慰剂组7.8%(P < 0.001)。
- 两项研究中risankizumab、ustekinumab和安慰剂组的不良事件频率相似。
核心结论
- Gordon等结论认为,risankizumab治疗中重度慢性斑块状银屑病的疗效高于安慰剂和ustekinumab,且各治疗组不良事件特征相似。
研究设计与样本
- 两项重复的III期双盲随机对照试验(UltIMMa-1和UltIMMa-2),在澳大利亚、奥地利、比利时、加拿大、捷克共和国、法国、德国、日本、墨西哥、波兰、葡萄牙、韩国、西班牙和美国共139个中心开展。
- UltIMMa-1纳入506例患者,UltIMMa-2纳入491例患者;患者有至少6个月的慢性斑块状银屑病病史。
- 患者随机接受150 mg risankizumab、45 mg或90 mg ustekinumab或安慰剂,按体重(大于或小于100 kg)和既往肿瘤坏死因子抑制剂暴露分层;安慰剂组在第16周转为risankizumab治疗。
- 研究药物在第0、4、16、28和40周给药;平行组对照研究持续至第16周。
主要发现
- UltIMMa-1中,第16周达到PASI 90的患者比例:risankizumab组75.3%,ustekinumab组42.0%,安慰剂组4.9%(P < 0.001,对比安慰剂和ustekinumab)。
- UltIMMa-1中,第16周达到sPGA 0或1的患者比例:risankizumab组87.6%,ustekinumab组63.0%,安慰剂组7.8%(P < 0.001,对比安慰剂和ustekinumab)。
- UltIMMa-2的结果与UltIMMa-1相似。
- 两项研究中risankizumab、ustekinumab和安慰剂组的不良事件频率相似。
关键数值与推荐
- 共同主要结局为第16周达到PASI 90(基线PASI降低≥90%)和sPGA评分为0或1(清除或几乎清除)的患者比例。
- 银屑病严重程度采用银屑病面积和严重程度指数(PASI)和静态医生整体评估(sPGA)测量。
- 作者还记录了各治疗组的不良事件数量和生活质量指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Gordon et al. investigated the efficacy and safety of risankizumab [an anti-interleukin (IL)-23p19 biologic] compared with ustekinumab (anti-IL-12/23p40) and placebo in patients with moderate-to-severe chronic plaque psoriasis. This was a parallel-group controlled study up to 16 weeks with a planned switch of the placebo group to risankizumab at 16 weeks. SETTING AND DESIGN: This study consisted of two replicate phase III, double-blinded randomized controlled trials (UltIMMa-1 and UltIMMa-2) conducted across 139 centres in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Japan, Mexico, Poland, Portugal, South Korea, Spain and the U.S.A. STUDY EXPOSURE: Patients with a minimum 6-month history of chronic plaque psoriasis were randomly assigned to receive either 150 mg risankizumab, 45 mg or 90 mg ustekinumab or placebo. Prior to this, each group was also stratified by weight (either more than or less than 100 kg) and previous exposure to tumour necrosis factor inhibitors. Those assigned to receive placebo were transitioned onto risankizumab at week 16. The study drugs were given at weeks 0, 4, 16, 28 and 40. OUTCOMES: The severity of psoriasis was measured using the Psoriasis Area and Severity Index (PASI) and a static Physician's Global Assessment (sPGA). The authors additionally recorded the number of adverse events in each treatment arm, and a measure of quality of life. PRIMARY OUTCOME MEASURES: The coprimary outcomes were the proportions of patients achieving ≥ 90% reduction in their baseline PASI (PASI 90) and an sPGA score of 0 or 1 (clear or almost clear) at week 16. RESULTS: In total 506 patients were included in UltIMMa-1 and 491 patients in UltIMMa-2. In UltIMMa-1, PASI 90 by week 16 was achieved by 75·3% of patients receiving risankizumab, compared with 42·0% receiving ustekinumab and 4·9% receiving placebo (P < 0·001 vs. placebo and ustekinumab). sPGA of 0 or 1 by week 16 was achieved by 87·6% of patients receiving risankizumab, compared with 63·0% receiving ustekinumab and 7·8% receiving placebo (P < 0·001 vs. placebo and ustekinumab). The results for UltIMMa-2 are similar. The frequencies of adverse events in the risankizumab, ustekinumab and placebo groups were similar in both studies. CONCLUSIONS: Gordon et al. conclude that risankizumab has a higher efficacy than placebo and ustekinumab in the treatment of moderate-to-severe chronic plaque psoriasis, and that the adverse-event profiles were similar across all treatment groups.
引用
- Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, et al. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. Br J Dermatol. 2019. PMID: 30632140. doi:10.1111/bjd.17624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。